BMC Nephrology最新文献

{"title":"Correction: Meprin β activity modulates cellular proliferation via trans-signaling IL-6-mediated AKT/ERK pathway in IR-induced kidney injury.","authors":"Shaymaa Abousaad, Faihaa Ahmed, Ayman Abouzeid, Christine Adhiambo, Elimelda Moige Ongeri","doi":"10.1186/s12882-025-04515-3","DOIUrl":"10.1186/s12882-025-04515-3","url":null,"abstract":"","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"548"},"PeriodicalIF":2.4,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microalbuminuria in children with cyanotic congenital heart disease in Enugu, Nigeria; a comparative study.","authors":"Sophia Adaeze Agomuo, Josephat Maduabuchi Chinawa, Fortune Amauche Ujunwa, Chikodi Felicitas Anarado, Uchenna Chiagoziem Nnajekwu, Daberechi Kenneth Adiele, Valerie Chizelum Okosi, Eberechukwu Chukwu, Henrietta Uchenna Okafor","doi":"10.1186/s12882-025-04472-x","DOIUrl":"10.1186/s12882-025-04472-x","url":null,"abstract":"<p><strong>Background: </strong>Children with congenital heart diseases are at increased risk of developing chronic kidney disease (CKD) later in life, and children with cyanotic congenital heart disease (CCHD) are at greater risk.</p><p><strong>Objectives: </strong>This study aimed to determine the prevalence of microalbuminuria and the associations between microalbuminuria and age, oxygen saturation and haematocrit in children with cyanotic congenital heart disease.</p><p><strong>Methods: </strong>This was a comparative, cross-sectional analytical study carried out over a period of six months. Thirty-six children with CCHD and thirty-six apparently healthy children were enrolled consecutively. Haematocrit levels, oxygen saturation, serum and urine creatinine levels and urine albumin levels were determined for eligible participants. A urine albumin/creatinine ratio in the range of 30-300 mg/g was classified as positive for microalbuminuria. Parametric and nonparametric tests were performed to determine the associations between the dependent and independent variables.</p><p><strong>Results: </strong>The prevalence rates of microalbuminuria were 38.9% (95% CI: 20.1, 56.5) and 5.6% (95% CI: 0.67, 18.7) in children with CCHD and in apparently healthy children, respectively. More children with CCHD than apparently healthy children had microalbuminuria. χ² = 11.57, COR = 10.8 (95% CI: 2.23, 52.29), p = 0.001. Compared with those without microalbuminuria, children with microalbuminuria had significantly higher haematocrits. χ² = 12.38, p = 0.001. Multivariate logistic regression revealed that a haematocrit ≥ 56% was a strong predictor of microalbuminuria in children with CCHD. AOR = 18.33 (95% CI: 2.52, 133.26), p = 0.004.</p><p><strong>Conclusion: </strong>This study demonstrated that children with CCHD are more likely to have microalbuminuria than are children who appear to be in good health and that microalbuminuria in this group of children is related to higher haematocrit levels. Early screening of this group of children is recommended to reduce the risk of progressive kidney disease.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"540"},"PeriodicalIF":2.4,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abemaciclib-associated acute interstitial nephritis successfully treated with glucocorticoids: a case report and literature review.","authors":"Mari Kumano, Yujiro Maeoka, Yuki Teragawa, Hiroki Yanagidani, Maria Yoshida, Akira Takahashi, Takao Masaki","doi":"10.1186/s12882-025-04442-3","DOIUrl":"10.1186/s12882-025-04442-3","url":null,"abstract":"<p><strong>Background: </strong>Drug-induced acute interstitial nephritis (DI-AIN) is the most common type of AIN. DI-AIN occurs when medications trigger a T cell-mediated immune response that promotes tubulitis and interstitial inflammation with eosinophils, often resulting in acute kidney injury (AKI) with nephromegaly. Recently, prolonged use of cyclin-dependent kinase (CDK) 4/6 inhibitors, as oral molecular-targeted drugs for breast cancer, was identified as a cause of AKI, including AIN and acute tubular necrosis (ATN). To date, there have been no reported cases of AIN associated with the use of abemaciclib, a CDK4/6 inhibitor.</p><p><strong>Case presentation: </strong>A 66-year-old Japanese woman presented with persistent diarrhea and nausea shortly after the initiation of abemaciclib for breast cancer and was subsequently referred to our hospital with severe renal dysfunction (blood urea nitrogen, 128.7 mg/dL; creatinine, 15.16 mg/dL). Based on her elevated renal tubular damage markers and bilateral renal enlargement, acute renal failure was suspected. A renal biopsy revealed interstitial infiltration of mononuclear cells and eosinophils, along with tubulitis and epithelial cell damage within the renal tubules, suggesting AIN caused by abemaciclib. The renal function improved with glucocorticoid therapy following fluid replacement for pre-renal AKI, and the serum creatinine decreased to approximately 2 mg/dL within 2 months.</p><p><strong>Conclusions: </strong>We report a case of biopsy-proven AIN that developed shortly after the initiation of abemaciclib, leading to severe renal dysfunction with nephromegaly. While prolonged use of CDK4/6 inhibitors can cause both AIN and ATN, AIN can also occur after short-term use, highlighting the importance of a renal biopsy to determine the need for glucocorticoid therapy.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"543"},"PeriodicalIF":2.4,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of thymopentin for infection prophylaxis in peritoneal dialysis patients: a retrospective study.","authors":"Xueying Chen, Yilin Ruan, Jingyuan Xie, Xiaomin Huang, Chunyan Zhang, Yan Cui, Tian Xu, Hong Ren","doi":"10.1186/s12882-025-04465-w","DOIUrl":"10.1186/s12882-025-04465-w","url":null,"abstract":"<p><strong>Background: </strong>Patients undergoing peritoneal dialysis are at high risk of infection, which significantly impacts morbidity and mortality. This retrospective study aimed to evaluate the association of thymopentin use with infection risk, immune function, and inflammatory markers in peritoneal dialysis patients.</p><p><strong>Methods: </strong>Clinical data from 100 patients undergoing peritoneal dialysis were collected and analyzed. According to the treatment regimens received, patients were divided into a control group (standard therapy) and a thymopentin group (standard therapy combined with thymopentin). Thymopentin was administered subcutaneously at a dose of 10 mg daily for the first 5 days, followed by 10 mg three times per week (Monday, Wednesday, and Friday) for 23 consecutive weeks. Patients were followed for a total of 48 weeks. Infection rates, immune function, and levels of inflammatory markers were compared between the two groups.</p><p><strong>Results: </strong>The thymopentin group demonstrated a lower infection incidence than the control group (0.73 vs. 1.00 per person-year). Thymopentin use was associated with significantly reduced overall infection rates (P < 0.001) and peritonitis (P = 0.031). Multivariate analysis confirmed a lower infection risk (HR = 0.54, 95% CI: 0.30-0.95; P = 0.034). Inflammatory markers showed favorable changes: interleukin-2 receptor (IL-2R) levels increased at 12 and 24 weeks (P = 0.002 and 0.020), interleukin-6 (IL-6) decreased at 12 weeks (P = 0.036). Serum albumin rose at both time points (P = 0.023 and 0.040). No significant changes were observed in CD3⁺/CD4⁺ or CD8⁺ T cells or the CD4/CD8 ratio.</p><p><strong>Conclusion: </strong>Thymopentin use was associated with reduced infection risk and favorable changes in inflammatory and nutritional markers among peritoneal dialysis patients. These findings suggest potential benefits of Thymopentin in this population.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"538"},"PeriodicalIF":2.4,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481784/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of telitacicept in IgA nephropathy: a propensity score matching analysis with a 6-month follow-up.","authors":"Hui Li, Ya Zhang, Chong Zhang","doi":"10.1186/s12882-025-04468-7","DOIUrl":"10.1186/s12882-025-04468-7","url":null,"abstract":"","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"546"},"PeriodicalIF":2.4,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A qualitative exploration of the patient disease and treatment burden of end stage renal failure, Post-Renal transplantation and antibody mediated rejection (AMR).","authors":"Nicola Barnes, Joshua Maher, Jane R Wells, Amy Clark, Nashmel Sargalo, Paul Cordero","doi":"10.1186/s12882-025-04415-6","DOIUrl":"10.1186/s12882-025-04415-6","url":null,"abstract":"<p><strong>Background: </strong>End stage renal disease (ESRD) is the irreversible decline in an individual's kidney function. In severe cases it can be fatal if dialysis or transplantation is not sought. Renal transplantation is associated with longer life expectancies and improved quality of life and is often the preferred treatment over chronic dialysis for those with ESRD. After kidney transplant, patients are at risk of infections, and complications such as allograft rejection. Antibody mediated rejection (AMR) is one of the most common causes of allograft failure. There is currently no approved medication for the prevention or treatment of AMR after transplantation. Whereas the patient-reported symptoms and impacts of ESRD and of kidney transplant have been widely documented, a paucity of these data specific to the population at high risk of or with active AMR is evident.</p><p><strong>Methods: </strong>We conducted qualitative interviews and analysis with 14 patients with ESRD on the waiting list for a kidney transplant, and 19 patients who had received a kidney transplant (patients post-transplant without AMR (n = 12), and patients post-transplant at high risk of or with active AMR (n = 7)).</p><p><strong>Results: </strong>A total of 52 symptoms and 69 impacts were reported across the populations with ESRD and post-transplant. New concepts emerged from the interviews that had not been reported in previous literature. The patients with AMR in our study reported mostly negative symptoms but continued to experience many benefits of transplant such as increased energy, an absence of dry or itching skin, an absence of urological and neuropathic symptoms and fewer symptoms overall. Negative impacts were most often related to emotional, physical, and social functioning, and positive impacts most frequently reported for overall health, activities of daily living and quality of life. Patients post-transplant both with and without AMR reported improvements in quality of life compared to before their transplant. However, although patients with AMR reported a number of positive impacts, fewer were mentioned, and less frequently than by patients post-transplant without AMR; a return to normalcy, increased social interaction, and improved diet and lifestyle are all examples of this. Our research allowed the development of a conceptual disease model specific to patients with AMR.</p><p><strong>Conclusion: </strong>The qualitative exploration of patient experience of symptoms and impacts carried out in our study underlines the heterogeneity of experience and the burden of disease and treatment experienced by patients at all stages of disease and treatment, from ESRD, to AMR of the kidney transplant. Eliciting these data directly from patients, analyzing and presenting these concepts in conceptual disease models is an essential step towards relevant and accurate measurement of patient experience in these populations.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"547"},"PeriodicalIF":2.4,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of commercial human primary mesangial cell, implications for experimental design.","authors":"Alva Johansson, Gayathri Narasimhan, Katharina Keuenhof, Roberto Boi, Kerstin Ebefors","doi":"10.1186/s12882-025-04444-1","DOIUrl":"10.1186/s12882-025-04444-1","url":null,"abstract":"<p><strong>Background: </strong>Mesangial cells (MCs) are involved in several glomerular diseases such as IgA nephropathy and diabetic kidney disease. In vitro work on human MCs is mainly conducted on primary MCs. However, cells from different donors could be significantly different, thus potentially affecting the outcome of the experiments.</p><p><strong>Method: </strong>We have compared commercially available primary human MCs from two different sources: HMCv1 and HMCv2. The cells were characterized using qPCR, western blot, and immunofluorescence. Response to PDGF-BB was assessed with proliferation assays, proteomics, and qPCR. Response to angiotensin II was assessed through contractility assay and response to IL-1β, diabetic milieu and TGFβ1 with qPCR.</p><p><strong>Results: </strong>Cells from both sources expressed mesangial markers. HMCv1, but not HMCv2, showed significant contractility in response to angiotensin II. Both HMCv1 and 2 significantly increased their proliferation rate in response to PDGF-BB. Proteomics revealed a stronger response to PDGF-BB for HMCv1 in respect to HMCv2, though similar pathways were regulated in both. IL-1β stimulus was stronger in HMCv1 in terms of increased expression of IL6 and CCL2/MCP1 mRNA. Diabetic milieu increased expression of IL-6 for both HMCv1 and 2, but significantly higher for HMCv1. TGFβ1 gave similar results in terms of IL-6 expression for cells from both sources. In addition, a list of 144 potential mesangial markers was compiled, that can be used for identification of MCs in omics data.</p><p><strong>Conclusion: </strong>This study shows that there are broad differences between sources of primary human MCs. The potential differences between clones of primary MCs need to be carefully considered when conducting in vitro experiments.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"539"},"PeriodicalIF":2.4,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kansas city cardiomyopathy questionnaire in cardiac function assessment of chronic kidney disease patients: a literature review.","authors":"Jiafang Li, Qunli Chen, Yi Xu","doi":"10.1186/s12882-025-04450-3","DOIUrl":"10.1186/s12882-025-04450-3","url":null,"abstract":"<p><p>Chronic kidney disease (CKD) patients face an increased risk of cardiovascular disease, particularly heart failure (HF). The combination of CKD and HF (CKD-HF) presents significant challenges in diagnosis, assessment, and management due to the unique pathophysiological features of this patient population. The Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported outcomes measure widely used in clinical trials of HF, shows promise in addressing these challenges. However, the effectiveness and application of KCCQ in CKD patients, especially those with heart failure, have not been fully explored. This article aims to review the current evidence of KCCQ in CKD patients, highlighting its potential value while acknowledging the limitations of current research, and suggesting potential clinical applications that warrant further validation.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"541"},"PeriodicalIF":2.4,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting panoptosis: a narrative review of its therapeutic potential in kidney disease.","authors":"Yuxin Guo, Yanru Zhao, Yanheng Qiao, Yunze Xing, Yaxuan Fang, Yuetong Zhao, Hanqi Yang, Yi Chen, Bo Yang","doi":"10.1186/s12882-025-04339-1","DOIUrl":"10.1186/s12882-025-04339-1","url":null,"abstract":"<p><p>Renal diseases are major global public health challenges due to their complex mechanisms and growing burden. PANoptosis, a unified programmed cell death pathway driven by the PANoptosome complex, involves the combined activation of pyroptotic, apoptotic, and necroptotic signaling, significantly contributing to renal tissue damage. This review systematically explores PANoptosis's composition, regulatory mechanisms, and its role in kidney pathologies such as AKI, CKD, DKD, and renal tumors. It also examines the interplay between PANoptosis and key cellular processes like mitochondrial dysfunction, ER stress, non - coding RNAs, ferroptosis, and autophagy. Preclinical studies suggest that targeting PANoptosis - related molecules (e.g., Z-DNA Binding Protein 1(ZBP1), caspase - 8, NOD-like receptor thermal protein domain associated protein 3(NLRP3)) shows therapeutic potential for kidney diseases. However, clinical application is currently limited due to insufficient human data. Future research should focus on validating PANoptosis biomarkers in renal diseases, developing cell - death - context - specific inhibitors and agonists, and clarifying its advantages over single - mode cell death modulation. This review highlights PANoptosis as a promising therapeutic strategy while addressing unresolved issues in nephrology research.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"545"},"PeriodicalIF":2.4,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The problem of segmenting global glomerulosclerosis in gigapixel histopathological images: the borderless glomeruli.","authors":"Luiz Souza, Jefferson Silva, Marcelo Mendonça, José Nathan, Angelo Duarte, Pinaki Sarder, Washington L C Dos-Santos, Luciano Oliveira","doi":"10.1186/s12882-025-04469-6","DOIUrl":"10.1186/s12882-025-04469-6","url":null,"abstract":"","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"544"},"PeriodicalIF":2.4,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}